Now that patients are being treated with something that prolongs their life and impacts the overall immune system in a positive way, new patterns are emerging that require new ways of classifying patients
If that is the case then they should have highlighted it instead of trying to compare it to historical studies that are now irrelevant because of the difference in trial designation.
PS I do think the OS data, long tail, and current survivors, bode well and is promising. Unfortunately nothing what it could be because of the........get this......lack of transparency! They presented and PR'd, now wouldn't it be great if they held a conference call like the other 95% of the companies to explain it to their investors?